PharmaJet

We are pleased to share that Tropis ID was used to immunize an additional 1.5 million children in the latest WHO polio eradication campaign in Pakistan. In total, Tropis has been used in campaigns and routine immunizations to protect nearly 12 million children against poliovirus. https://lnkd.in/gURDuFaU

PharmaJet congratulates Dr. Sonia Resik and her research team on their recent Vaccine journal publication titled: "Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba." The researchers found that: "The safety and acceptability associated with the use of the Tropis needle-free injector for intradermal administration of inactivated polio vaccine at 4 and 8 months of age in the national immunization program was favorable..." "There were significantly less adverse events associated with Tropis than with needle and syringe (N/S)." "98 % of parents and 98.5 % of nurses preferred Tropis over N/S." "Final seroprevalence levels were not significantly different between Tropis and N/S." Please see the article link below! https://lnkd.in/g2HCH2fH

PharmaJet congratulates Dr. Sonia Resik and her research team on their recent Vaccine journal publication titled: "Tropis needle-free injector for fractional-dose IPV administration: A pilot study for integration into routine immunization services in Cuba." The researchers found that: "The safety and acceptability associated with the use of the Tropis needle-free injector for intradermal administration of inactivated polio vaccine at 4 and 8 months of age in the national immunization program was favorable..." "There were significantly less adverse events associated with Tropis than with needle and syringe (N/S)." "98 % of parents and 98.5 % of nurses preferred Tropis over N/S." "Final seroprevalence levels were not significantly different between Tropis and N/S." Please see the article link below! https://lnkd.in/g2HCH2fH

PharmaJet? will present its latest routine immunization study at the 61st Annual Medical Conference & International Health Exhibition on February 21-22, 2025, in Addis Ababa, Ethiopia. Paul LaBarre, MME, MBA, VP of Global Business Development, will discuss intradermal needle-free vaccine delivery and its potential to reduce Ethiopia’s immunization costs and improve coverage. The event will gather physicians, medical associations, health ministries, and industry partners. #PharmaJet #PublicHealth #Ethiopia #HealthcareInnovation #GlobalHealth #GIawards #GazetInternational #GI

I am looking forward to presenting PharmaJet's latest implementation research on Saturday at the 61st Annual Medical Conference & International Health Exhibition on February 21-22, 2025, in Addis Ababa, Ethiopia. Leveraging recent evidence from Tropis use in campaigns and routine immunization in Pakistan,?Somalia,?and Nigeria,?we look forward to working with the Ethiopian Ministry of Health and other African partners to assess the benefits needle-free ID delivery can provide for their immunization programs. https://lnkd.in/gBmmmd4U

We are pleased to announce the publication in NPJ Vaccines of the USAMRIID phase 1 clinical trial results showing PharmaJet needle-free IM delivery of Hantavirus DNA vaccines induces the production of a robust and durable immune response. Read the release here: https://lnkd.in/gMkvWUxi

Come to the PharmaJet Presentation at ASTMH this week and speak with our experts to find out more about how our innovative intradermal needle-free delivery system can improve the performance and outcomes of your pipeline vaccines through improved activation of the immune system and improved implementation coverage.

PharmaJet Scientific Affairs Manager, Dr. Carmen Ledesma-Feliciano will be presenting a poster tomorrow, November 13, at the International mRNA Health Conference 2024. The poster, entitled Modulating Immune Responses to mRNA Vaccines Using Needle-Free Delivery Technologies, will highlight recent published studies that show how PharmaJet needle-free delivery can enhance immune response of mRNA vaccines and highlight where it has been successfully adopted into multiple vaccine development programs. https://lnkd.in/g9xd9-cm

Our own Gregg Wilson, Director of Medical and Scientific Affairs at PharmaJet, will be presenting a poster this Friday, November 8, at the Society of Immunotherapy of Cancer (SITC) conference. The poster will focus on how PharmaJet needle-free technology can improve DNA vaccine delivery and how it has been successfully adopted into multiple cancer vaccine development programs. #vaccineswork, #needlefree, #cancertherapeutics https://lnkd.in/gEKi2H_P

PharmaJet is proud to contribute to the polio eradication effort! Needle-free can improve coverage rates, reduce costs, and enable house-to-house campaigns!